New cancer treatments are being discovered all the time, and recently a new one was found for renal cell carcinoma.
Nearly 50 new targeted therapies are released every month, and approximately 500 new studies on cancer alone released each week.
However, many of these new therapies can take years to become available through public health care in Canada, if at all, because of the the public healthcare system’s limitations with time and budget.
Access the Newest Cancer Treatments
Often, the only way to access these superior treatments is through a precision oncology service like CTOAM (Cancer Treatment Options and Management).
Our precision oncology consultants use genetic testing to determine the mutations that are driving your cancer and match those to the newest targeted drugs available. Because CTOAM’s cancer experts stay up-to-date with the latest peer-reviewed cancer research, they can recommend exactly which new treatment(s) will be most effective for your unique form of cancer. And they’ll help you and your treatment team access them.
To learn how CTOAM can help you access superior testing and treatments than conventional cancer care has to offer, register today for a Precision Second Opinion.
New Targeted Treatment Option for Patients with Renal Cell Carcinoma
Renal cell carcinoma (RCC) is tough to treat. A recent study has revealed that a new treatment, Cabozantinib, is more effective for patients with bone metastasis from advanced RCC than Everolimus.
About the Study
Cabozantinib was associated with improved outcomes versus Everolimus in patients with bone metastases. Median progression-free survival was 7.4 versus 2.7 months.
In the trial, 658 patients with advanced RCC (after previous vascular endothelial growth factor receptor inhibitor therapy) received either Cabozantinib at 60 mg or Everolimus at 10 mg daily.
Among all patients, Cabozantinib was associated with improved progression-free survival (PFS), overall survival (OS), and objective response rate (OR). The current prespecified subgroup analysis was based on baseline bone metastasis status according to an independent radiology committee (IRC).
Among the 77 Cabozantinib and 65 Everolimus recipients with bone metastases at baseline, median PFS was 7.4 months versus 2.7 months; median OS was 20.1 months versus 12.1 months; and ORR according to IRC was 17% versus 0%. Skeletal-related events occurred in 23% versus 29% of patients, and bone scan response rates were 20% vs 10%. The safety profiles of Cabozantinib and Everolimus in patients with bone metastases were consistent with those in patients without bone metastases. Read more about the study here.
Significantly, PFS, OS, and ORR were also improved among Cabozantinib recipients without bone metastases – patients treated with Cabozantinib had greater changes in bone biomarkers, on all fronts.
Study Conclusions
The investigators concluded, “Cabozantinib treatment was associated with improved [PFS, OS, and ORR] when compared with Everolimus treatment in patients with advanced RCC and bone metastases and represents a good treatment option for these patients.”
When it Comes to Cancer, Knowledge is Power!
This is another example of how important it is to look at treatment options beyond those offered by conventional cancer care. Targeted treatments often add years to a patient’s life, improve their quality of life, and significantly improve their chances of becoming cancer-free.
Get a Precision Second Opinion today to discover how you can enhance your current cancer care with precision oncology. And don’t worry: with CTOAM, you can continue to work with your public oncologist and cancer care clinic while you benefit from the advanced testing and treatment that we help you access.
You have nothing to lose and years, if not a lifetime, to gain…
on May 22, 2018